Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

2.

Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection.

Baeza Garcia A, Siu E, Sun T, Exler V, Brito L, Hekele A, Otten G, Augustijn K, Janse CJ, Ulmer JB, Bernhagen J, Fikrig E, Geall A, Bucala R.

Nat Commun. 2018 Jul 13;9(1):2714. doi: 10.1038/s41467-018-05041-7.

3.

Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators.

Lodaya RN, Brito LA, Wu TYH, Miller AT, Otten GR, Singh M, O'Hagan DT.

J Pharm Sci. 2018 Sep;107(9):2310-2314. doi: 10.1016/j.xphs.2018.05.012. Epub 2018 Jun 5.

PMID:
29883663
4.

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.

Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB, Zolla-Pazner S, Liao HX, Haynes BF, Michael NL, Kim JH, Rao M, O'Connell RJ, Carfi A, Barnett SW.

PLoS One. 2018 Apr 26;13(4):e0194266. doi: 10.1371/journal.pone.0194266. eCollection 2018.

5.

The Preparation and Physicochemical Characterization of Aluminum Hydroxide/TLR7a, a Novel Vaccine Adjuvant Comprising a Small Molecule Adsorbed to Aluminum Hydroxide.

Malyala P, Laera D, Cianetti S, Bufali S, Aggravi M, Ianni E, Judge C, Otten G, Singh M, O'Hagan DT.

J Pharm Sci. 2018 Jun;107(6):1577-1585. doi: 10.1016/j.xphs.2018.01.024. Epub 2018 Feb 6.

PMID:
29421216
6.

Defining Y-SNP variation among the Flemish population (Western Europe) by full genome sequencing.

Larmuseau MHD, Otten GPPL, Decorte R, Van Damme P, Moisse M.

Forensic Sci Int Genet. 2017 Nov;31:e12-e16. doi: 10.1016/j.fsigen.2017.10.008. Epub 2017 Oct 28.

PMID:
29089250
7.

Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.

Pepini T, Pulichino AM, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, Debasitis JC, Maruggi G, Otten GR, Geall AJ, Yu D, Ulmer JB, Iavarone C.

J Immunol. 2017 May 15;198(10):4012-4024. doi: 10.4049/jimmunol.1601877. Epub 2017 Apr 17.

8.

Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity.

Carroll B, Maetzel D, Maddocks OD, Otten G, Ratcliff M, Smith GR, Dunlop EA, Passos JF, Davies OR, Jaenisch R, Tee AR, Sarkar S, Korolchuk VI.

Elife. 2016 Jan 7;5. pii: e11058. doi: 10.7554/eLife.11058.

9.

Self-amplifying mRNA vaccines.

Brito LA, Kommareddy S, Maione D, Uematsu Y, Giovani C, Berlanda Scorza F, Otten GR, Yu D, Mandl CW, Mason PW, Dormitzer PR, Ulmer JB, Geall AJ.

Adv Genet. 2015;89:179-233. doi: 10.1016/bs.adgen.2014.10.005. Epub 2014 Dec 4.

PMID:
25620012
10.

Performance characterization of a broadband vector Apodizing Phase Plate coronagraph.

Otten GP, Snik F, Kenworthy MA, Miskiewicz MN, Escuti MJ.

Opt Express. 2014 Dec 1;22(24):30287-314. doi: 10.1364/OE.22.030287.

PMID:
25606959
11.

The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance.

Shah RR, Dodd S, Schaefer M, Ugozzoli M, Singh M, Otten GR, Amiji MM, O'Hagan DT, Brito LA.

J Pharm Sci. 2015 Apr;104(4):1352-61. doi: 10.1002/jps.24337. Epub 2015 Jan 19.

PMID:
25600347
12.

Rational design of small molecules as vaccine adjuvants.

Wu TY, Singh M, Miller AT, De Gregorio E, Doro F, D'Oro U, Skibinski DA, Mbow ML, Bufali S, Herman AE, Cortez A, Li Y, Nayak BP, Tritto E, Filippi CM, Otten GR, Brito LA, Monaci E, Li C, Aprea S, Valentini S, Calabrό S, Laera D, Brunelli B, Caproni E, Malyala P, Panchal RG, Warren TK, Bavari S, O'Hagan DT, Cooke MP, Valiante NM.

Sci Transl Med. 2014 Nov 19;6(263):263ra160. doi: 10.1126/scitranslmed.3009980.

13.

Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.

Bogers WM, Oostermeijer H, Mooij P, Koopman G, Verschoor EJ, Davis D, Ulmer JB, Brito LA, Cu Y, Banerjee K, Otten GR, Burke B, Dey A, Heeney JL, Shen X, Tomaras GD, Labranche C, Montefiori DC, Liao HX, Haynes B, Geall AJ, Barnett SW.

J Infect Dis. 2015 Mar 15;211(6):947-55. doi: 10.1093/infdis/jiu522. Epub 2014 Sep 18.

14.

Fast & Furious focal-plane wavefront sensing.

Korkiakoski V, Keller CU, Doelman N, Kenworthy M, Otten G, Verhaegen M.

Appl Opt. 2014 Jul 10;53(20):4565-79. doi: 10.1364/AO.53.004565.

PMID:
25090079
15.

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, Archer J, Seubert A, Otten GR, Beard CW, Dey AK, Lilja A, Valiante NM, Mason PW, Mandl CW, Barnett SW, Dormitzer PR, Ulmer JB, Singh M, O'Hagan DT, Geall AJ.

Mol Ther. 2014 Dec;22(12):2118-29. doi: 10.1038/mt.2014.133. Epub 2014 Jul 16.

16.

Calibrating a high-resolution wavefront corrector with a static focal-plane camera.

Korkiakoski V, Doelman N, Codona J, Kenworthy M, Otten G, Keller CU.

Appl Opt. 2013 Nov 1;52(31):7554-63. doi: 10.1364/AO.52.007554.

PMID:
24216658
17.

Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity.

Maruggi G, Shaw CA, Otten GR, Mason PW, Beard CW.

Virology. 2013 Dec;447(1-2):254-64. doi: 10.1016/j.virol.2013.07.021. Epub 2013 Oct 5.

18.

Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini D, Maione D, Qi ZQ, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E, Mandl CW, Mason PW, Settembre EC, Ulmer JB, Craig Venter J, Dormitzer PR, Rappuoli R, Geall AJ.

Emerg Microbes Infect. 2013 Aug;2(8):e52. doi: 10.1038/emi.2013.54. Epub 2013 Aug 14.

19.

Generation of a parvovirus B19 vaccine candidate.

Chandramouli S, Medina-Selby A, Coit D, Schaefer M, Spencer T, Brito LA, Zhang P, Otten G, Mandl CW, Mason PW, Dormitzer PR, Settembre EC.

Vaccine. 2013 Aug 20;31(37):3872-8. doi: 10.1016/j.vaccine.2013.06.062. Epub 2013 Jul 2.

PMID:
23827313
20.

Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ.

Cu Y, Broderick KE, Banerjee K, Hickman J, Otten G, Barnett S, Kichaev G, Sardesai NY, Ulmer JB, Geall A.

Vaccines (Basel). 2013 Aug 22;1(3):367-83. doi: 10.3390/vaccines1030367.

21.

The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease.

Shaw CA, Galarneau JR, Bowenkamp KE, Swanson KA, Palmer GA, Palladino G, Markovits JE, Valiante NM, Dormitzer PR, Otten GR.

Vaccine. 2013 Jan 2;31(2):306-12. doi: 10.1016/j.vaccine.2012.11.006. Epub 2012 Nov 12.

PMID:
23153444
22.

Nonviral delivery of self-amplifying RNA vaccines.

Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9. doi: 10.1073/pnas.1209367109. Epub 2012 Aug 20.

23.

MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine.

Singh M, Kazzaz J, Ugozzoli M, Baudner B, Pizza M, Giuliani M, Hawkins LD, Otten G, O'Hagan DT.

Hum Vaccin Immunother. 2012 Apr;8(4):486-90. doi: 10.4161/hv.19229.

PMID:
22832252
24.

Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

Uematsu Y, Vajdy M, Lian Y, Perri S, Greer CE, Legg HS, Galli G, Saletti G, Otten GR, Rappuoli R, Barnett SW, Polo JM.

Clin Vaccine Immunol. 2012 Jul;19(7):991-8. doi: 10.1128/CVI.00031-12. Epub 2012 May 23.

25.

The influence of bedding materials on bio-aerosol exposure in dairy barns.

Samadi S, van Eerdenburg FJ, Jamshidifard AR, Otten GP, Droppert M, Heederik DJ, Wouters IM.

J Expo Sci Environ Epidemiol. 2012 Jul;22(4):361-8. doi: 10.1038/jes.2012.25. Epub 2012 May 2.

PMID:
22549719
26.

A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding.

Iavarone C, Ramsauer K, Kubarenko AV, Debasitis JC, Leykin I, Weber AN, Siggs OM, Beutler B, Zhang P, Otten G, D'Oro U, Valiante NM, Mbow ML, Visintin A.

J Immunol. 2011 Apr 1;186(7):4213-22. doi: 10.4049/jimmunol.1003585. Epub 2011 Mar 7.

27.

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

Barnett SW, Burke B, Sun Y, Kan E, Legg H, Lian Y, Bost K, Zhou F, Goodsell A, Zur Megede J, Polo J, Donnelly J, Ulmer J, Otten GR, Miller CJ, Vajdy M, Srivastava IK.

J Virol. 2010 Jun;84(12):5975-85. doi: 10.1128/JVI.02533-09. Epub 2010 Apr 14.

28.

Antibody affinity maturation and respiratory syncytial virus disease.

Shaw CA, Otten G, Wack A, Palmer GA, Mandl CW, Mbow ML, Valiante N, Dormitzer PR.

Nat Med. 2009 Jul;15(7):725; author reply 725-6. doi: 10.1038/nm0709-725a. No abstract available.

PMID:
19584854
29.

A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.

zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A, Hebblewaite D, Sites D, Nieves-Duran L, Srivastava R, Otten GR, Rabussay D, Zhang L, Ulmer JB, Barnett SW, Donnelly JJ.

AIDS Res Hum Retroviruses. 2008 Aug;24(8):1103-16. doi: 10.1089/aid.2008.0055.

30.

Flow cytometry analysis using the Becton Dickinson FACS Calibur.

Holmes KL, Otten G, Yokoyama WM.

Curr Protoc Immunol. 2002 Aug;Chapter 5:Unit 5.4. doi: 10.1002/0471142735.im0504s49.

PMID:
18432885
31.

Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.

Megede JZ, Otten GR, Doe B, Liu H, Srivastava R, Greer C, Legg H, Tang T, Polo JM, Donnelly JJ, Ulmer JB, Barnett SW.

Vaccine. 2006 Apr 5;24(15):2755-63. Epub 2006 Jan 19.

PMID:
16460840
32.

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.

Lian Y, Srivastava I, Gómez-Román VR, Zur Megede J, Sun Y, Kan E, Hilt S, Engelbrecht S, Himathongkham S, Luciw PA, Otten G, Ulmer JB, Donnelly JJ, Rabussay D, Montefiori D, van Rensburg EJ, Barnett SW.

J Virol. 2005 Nov;79(21):13338-49.

33.

Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.

Otten GR, Schaefer M, Doe B, Liu H, Megede JZ, Donnelly J, Rabussay D, Barnett S, Ulmer JB.

Vaccine. 2006 May 22;24(21):4503-9. Epub 2005 Aug 19.

PMID:
16181711
34.

Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins.

Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede Jz, Kazzaz J, Lian Y, Singh M, Ugozzoli M, Montefiori D, Lewis M, Driver DA, Dubensky T, Polo JM, Donnelly J, O'Hagan DT, Barnett S, Ulmer JB.

J Virol. 2005 Jul;79(13):8189-200.

35.

Enhancement of DNA vaccine potency in rhesus macaques by electroporation.

Otten G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J, O'Hagan D, Donnelly J, Widera G, Rabussay D, Lewis MG, Barnett S, Ulmer JB.

Vaccine. 2004 Jun 23;22(19):2489-93.

PMID:
15193413
36.

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.

Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, Romero RE, Tang Z, Bin Q, Dubensky TW Jr, Vajdy M, Otten GR, Polo JM.

J Virol. 2003 Oct;77(19):10394-403.

37.

Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.

zur Megede J, Otten GR, Doe B, Liu H, Leung L, Ulmer JB, Donnelly JJ, Barnett SW.

J Virol. 2003 Jun;77(11):6197-207.

38.

Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.

Otten G, Schaefer M, Greer C, Calderon-Cacia M, Coit D, Kazzaz J, Medina-Selby A, Selby M, Singh M, Ugozzoli M, zur Megede J, Barnett SW, O'Hagan D, Donnelly J, Ulmer J.

J Virol. 2003 May;77(10):6087-92.

39.

Quantitative assessment of antigen-specific CD8+ T cells in the mouse: application to vaccine research.

Otten GR, Chen M, Doe B, zur Megede J, Barnett S, Ulmer J.

Immunol Lett. 2003 Jan 22;85(2):215-22.

PMID:
12527230
40.
41.
42.

Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines.

O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, Schaefer M, Doe B, Otten GR, Ulmer JB.

J Virol. 2001 Oct;75(19):9037-43.

43.

Modelling the effects of (green) antifungals, droplet size distribution and temperature on mould outgrowth in water-in-oil emulsions.

ter Steeg PF, Otten GD, Alderliesten M, de Weijer R, Naaktgeboren G, Bijl J, Vasbinder AJ, Kershof I, van Duijvendijk AM.

Int J Food Microbiol. 2001 Aug 5;67(3):227-39.

PMID:
11518432
44.

Relative potency of cellular and humoral immune responses induced by DNA vaccination.

Otten GR, Doe B, Schaefer M, Chen M, Selby MJ, Goldbeck C, Hong M, Xu F, Ulmer JB.

Intervirology. 2000;43(4-6):227-32.

PMID:
11251378
45.

Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein.

Gardner JP, Frolov I, Perri S, Ji Y, MacKichan ML, zur Megede J, Chen M, Belli BA, Driver DA, Sherrill S, Greer CE, Otten GR, Barnett SW, Liu MA, Dubensky TW, Polo JM.

J Virol. 2000 Dec;74(24):11849-57.

46.

Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice.

Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, Otten GR, Ulmer JB, Donnelly JJ, Ott G, McDonald DM.

J Immunol. 2000 Sep 1;165(5):2850-8.

47.

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo.

Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ, Ulmer JB.

J Immunol. 2000 May 1;164(9):4635-40.

48.

Quantification of the number of cytotoxic T cells specific for an immunodominant HCV-specific CTL epitope primed by DNA immunization.

Lee AY, Polakos NK, Otten GR, Ulmer JB, Houghton M, Paliard X.

Vaccine. 2000 Mar 17;18(18):1962-8.

PMID:
10699347
49.

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.

zur Megede J, Chen MC, Doe B, Schaefer M, Greer CE, Selby M, Otten GR, Barnett SW.

J Virol. 2000 Mar;74(6):2628-35.

50.

Regulation of gene expression in vivo following transduction by two separate rAAV vectors.

Rendahl KG, Leff SE, Otten GR, Spratt SK, Bohl D, Van Roey M, Donahue BA, Cohen LK, Mandel RJ, Danos O, Snyder RO.

Nat Biotechnol. 1998 Aug;16(8):757-61.

PMID:
9702775

Supplemental Content

Support Center